Silencing of TBX2 in cisplatin-resistant breast tumor tissues disrupts the ATM-CHK2-p53 signaling pathway, increasing the drug sensitivity of breast tumor to cisplatin. This evidence concerns the gene TP53 and breast neoplasm.